MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MacroGenics reports revenue growth and promising clinical updates in Q4

MacroGenics delivered strong financial performance with revenue growth and cost reductions in 2022.
The company faces challenges in study modifications, dose optimization, and patient evaluation for its key products.
Opportunities lie in expanding product studies, strategic partnerships, and optimizing treatment efficacy.
Overall, MacroGenics shows promise in financial stability, product development, and market positioning.

MacroGenics reports Q1 revenue growth amidst net loss challenges

MacroGenics showed mixed financial performance in Q1 2023 with revenue growth but a significant net loss.
The company's strengths lie in its anticipated cash runway, FDA approvals, and expected milestone payments.
Challenges include managing expenses, improving financial performance, and addressing analyst inquiries.
Opportunities exist in revenue growth, clinical programs, FDA approvals, and strategic partnerships.

MacroGenics reports Q2 results, projects strong pipeline growth ahead

MacroGenics' Q2 2023 performance reflects mixed financial results but strong progress in pipeline development and strategic partnerships.
The company's financial stability, ongoing innovation, and revenue potential position it well for future growth and value creation.
Challenges in data disclosure, enrollment criteria, and dose optimization require careful navigation, but present opportunities for market expansion and program enhancement.

MacroGenics reports improved Q3 earnings, eyes strategic partnerships for growth

MacroGenics demonstrated improved financial performance in Q3 2023, with a focus on cost management and strategic pipeline advancements.
The company's efforts to secure non-dilutive capital, explore partnerships, and drive innovation in ADC development position it for future growth.
Challenges lie in revenue generation, market differentiation, and resource allocation, but opportunities exist in collaborations, tumor type expansion, and technological advancements.

MacroGenics reports revenue decline but advances in clinical programs

MacroGenics faced a decline in revenue but made progress in its clinical programs and pipeline advancements.
Challenges include data transparency, patient enrollment, and managing treatment side effects.
Opportunities lie in potential Phase III trials, revenue growth prospects, and advancements in patient treatment.

MacroGenics reports strong Q1 results, eyes expansion and combination therapies

MacroGenics' Q1 2024 performance showed promising results with strong revenue and ongoing research advancements.
The company's focus on expanding studies, improving tolerability, and exploring combination therapies presents growth opportunities.
Challenges include ongoing investigations into safety protocols and evaluation of patient outcomes.
Overall, MacroGenics' strategic plans and positive efficacy outcomes position them well for future growth and development.

MacroGenics reports stellar Q3 earnings, CEO transition announced

MacroGenics delivered impressive financial results in Q3 2024, marked by substantial revenue growth, increased net income, and a solid cash balance supported by strategic initiatives.
While facing challenges in managing rising expenses and navigating a CEO transition, the company's diverse clinical pipeline and strong financial position present opportunities for future growth and innovation.
Investors should monitor how MacroGenics addresses cost management, sustains operational momentum during leadership changes, and capitalizes on its strengths to drive continued success in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm has initiated an investigation into claims against MacroGenics, Inc. (MGNX) and is urging its investors to reach out

LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm has begun a probe into allegations against MacroGenics, Inc. (MGNX) and encourages its investors to make contact

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Inquiry Into Allegations Against MacroGenics, Inc. (MGNX) And Encourages Its Investors To Make Contact

NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.

Investors who Lost Money on MacroGenics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - MGNX

LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Investigation Into Claims Against MacroGenics, Inc. (MGNX) And Calls For Investors To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Launches Inquiry into Allegations Against MacroGenics, Inc. and Encourages Investors to Communicate

NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.

MGNX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if You Lost Money on Your MacroGenics, Inc. Investment

LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

MGNX CRUCIAL INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of MacroGenics, Inc. ("MacroGenics, Inc.") (NASDAQ:MGNX) concerning possible violations of federal securities laws. On April 3, 2024, the Company issued a press released describing a research abstract it submitted about the TAMARACK study.

Shareholder Rights Advocates at Levi & Korsinsky Investigate MacroGenics, Inc. (MGNX) Regarding Possible Securities Fraud Violations

LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

Alkermes

Viking Therapeutics

As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised for a resurgence.

3 Biotech Stocks That Could Be Millionaire-Makers: May Edition

LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES , May 14, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofMacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $MGNX #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). The investigation concerns whether MacroGenics and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On May 10, 2024, MacroGenics provided investors with a clinical trial update as part of its recent earn.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)

MacroGenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial. MacroGenics has between 4 and 5 quarters of cash and investments on hand.

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

Macrogenics (NASDAQ: MGNX ) stock is dropping hard on Friday after the after providing investors with a clinical trial update in its latest earnings report. The news that has investors spooked today has to do with fatalities during Macrogenics' TAMARACK study.

Why Is Macrogenics (MGNX) Stock Down 69% Today?

MacroGenics, Inc. (NASDAQ:MGNX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Call Participants Tara Bancroft - TD Cowen Jonathan Chang - Leerink Partners Ashiq Mubarack - Citi Kaveri Pohlman - BTIG Stephen Willey - Stifel John Miller - Evercore Etzer Darout - BMO Capital Markets Mayank Mamtani - B. Riley Securities Silvan Tuerkcan - Citizens JMP Securities Kelsey Goodwin - Guggenheim Partners Peter Lawson - Barclays Operator Good afternoon.

MacroGenics, Inc. (MGNX) Q1 2024 Earnings Call Transcript

ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024.

MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data

ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET.

MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call

Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024.

News for MacroGenics Stock (MGNX)